Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, University of Bisha, 255, Al Nakhil, Bisha 67714, Saudi Arabia.
Department of Medical Laboratory Sciences, College of Applied Medical Sciences, University of Bisha, P.O. Box 255, Bisha 67714, Saudi Arabia.
Pathol Res Pract. 2024 Nov;263:155568. doi: 10.1016/j.prp.2024.155568. Epub 2024 Aug 29.
This review investigates the regulatory role of non-coding RNAs (ncRNAs) in estrogen receptor (ER) signaling pathways, particularly in the context of breast cancer therapy, with an emphasis on the emerging potential of nanotechnology for drug delivery. The information was obtained from reputable databases, including PubMed, Elsevier, Springer, Wiley, Taylor, and Francis, which contain past and present research. Breast cancer remains the most prevalent cancer among women worldwide, and ER signaling mechanisms heavily influence its progression. Treatment options have traditionally encompassed surgery, chemotherapy, radiation therapy, targeted therapy, and hormone therapy. In recent decades, nanomedicine has emerged as a promising approach to breast cancer treatment. By passively targeting tumor cells and reducing toxicity, nanodrugs can overcome the challenges of conventional chemotherapy. Additionally, nanocarriers can stimulate tumor cells, enhancing treatment efficacy. Recent advancements in nanomedicine offer promising approaches for targeted cancer therapy, potentially overcoming the limitations of conventional treatments. This review explores the interactions between long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) with ER pathways, their impact on breast cancer progression, and how these interactions can be leveraged to enhance therapeutic efficacy through nanotechnology-based drug delivery systems.
这篇综述探讨了非编码 RNA（ncRNAs）在雌激素受体（ER）信号通路中的调控作用，特别是在乳腺癌治疗方面，并强调了纳米技术在药物传递方面的新兴潜力。信息来自于可靠的数据库，包括 PubMed、Elsevier、Springer、Wiley、Taylor 和 Francis，这些数据库包含过去和现在的研究。乳腺癌仍然是全球女性中最常见的癌症，ER 信号机制对其进展有很大影响。治疗选择传统上包括手术、化疗、放疗、靶向治疗和激素治疗。在过去几十年中，纳米医学已成为治疗乳腺癌的一种有前途的方法。通过被动靶向肿瘤细胞和降低毒性，纳米药物可以克服传统化疗的挑战。此外，纳米载体可以刺激肿瘤细胞，增强治疗效果。纳米医学的最新进展为靶向癌症治疗提供了有前途的方法，可能克服传统治疗的局限性。这篇综述探讨了长非编码 RNA（lncRNAs）和 microRNAs（miRNAs）与 ER 途径的相互作用，它们对乳腺癌进展的影响，以及如何利用这些相互作用通过基于纳米技术的药物传递系统来提高治疗效果。
